Cas No.Product NameDescription
379231-04-6AZD0530Saracatinib (AZD0530) is a highly selective, orally available, dual-specific Src/Abl kinase inhibitor with IC50 of 2.7 and 30 nM for c-Src and Abl kinase, respectively.
943319-70-8PonatinibPonatinib (AP24534) is a novel potent, orally available small molecule multitargeted kinase inhibitor with IC50 of 0.37, 2, 1.5, 2.2, 1.1, 1and 0.24 nM for native pan-BCR-ABL, mutated form, VEGFR2, FGFR1, PDGFRα, mutant FLT3 phosphorylation and LYN.
940310-85-0NVP-BHG712NVP-BHG712 is a small molecule specific EphB4, VEGFR2, c-raf, c-src and c-Abl kinase inhibitor with ED50 of 25 nM, 4.2, 0.4, 1.3 and 1.7μM, respectively.
887650-05-7BafetinibBafetinib ist ein Hemmstoff von Tyrosinkinasen. Es beeinflusst die Bildung des Fusionsproteins Bcr-Abl, als auch die des Enzyms Lyn-Kinase und soll bei M?usen zehnmal st?rker wirken als der eingeführte Tyrosinkinasehemmstoff Imatinib.
896466-76-5AT9283AT9283 is a small molecule a multi-targeted c-ABL, JAK2, Aurora A and B inhibitor with of 4, 1.2, 1.1 and approximate 3 nM for Bcr-Abl(T3151), Jak2 and Jak3, aurora A and B, respectively.
827318-97-8DanusertibDanusertib (PHA-739358) is a pyrrolo-pyrazole and small molecule Aurora kinases and Bcr-Abl kinase inhibitor with IC50 of 13, 79, and 61 nM for Aurora A, B, and C, respectively.
302962-49-8DasatinibDasatinib also known as BMS-354825, Sprycel, is ATP-competitive, dual SRC/ABL inhibitor.
162359-56-0FTY720Fingolimod is Src-bcr-Abl Inhibitor & S1P receptor agonist with IC50 of 0.137, 10.98 nM for (S)- and (R)- FTY720-phosphate.
1020172-07-9DCC-2036DCC-2036, potently inhibits both unphosphorylated and phosphorylated ABL1 by inducing a type II inactive conformation.
856243-80-6WP1130WP1130 is a novel selective small molecular deubiquitinase (DUB) inhibitor and a Bcr/Abl destruction pathway activator with an IC50 of 1.8 μM for K562 cells.
897016-82-9KX-01KX2-391 is an orally bioavailable small molecule Src kinase inhibitor with potential antineoplastic activity.
1038395-65-1KX2-391(2HCl)KX2-391 (KX01), the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.
778270-11-4GNF-2GNF-2 is a highly selective non-ATP competitive inhibitor of Bcr-Abl, shows no activity to Flt3-ITD, Tel-PDGFR, TPR-MET and Tel-JAK1 transformed tumor cells.
1355326-35-0AGI-5198AGI-5198, a novel R132H-IDH1 inhibitor, identified through a high-throughput screen blocked, in a dose-dependent manner, the ability of the mutant enzyme (mIDH1) to produce R-2-hydroxyglutarate (R-2HG).
172889-27-9PP2PP2 is a potent, reversible, ATP-competitive, and selective inhibitor of the Src family of protein tyrosine kinases.
895519-91-2FluMatinib MesylateFlumatinib,a derivative of imatinib, is a multi-kinase inhibitor with IC50 Values of 1.2 nM, 307.6 nM and 2662 nM for c-Abl, PDGFRβ and c-Kit respectively.
221243-82-91-NA-PP11-NA-PP1 is a reversible, cell-permeable inhibitor of Src-family tyrosine kinases that have been mutated, by a single base substitution, to become ‘analog sensitive’ , as compared to the wild-type kinase.
2609-46-3AmilorideAmiloride is a potent epithelial sodium channel blocker.

First Previous Next End   Jump to  Page
Cell Cycle/Checkpoint
Angiogenesis/Tyrosine Kinase
Apoptosis Pathway
Aurora/Ksp Pathway
MAPK Pathway
Hormone Pathay
Proteases/HSP90/HSP70 Pathway
Wnt/Hedgehog/Notch Pathway
Jak/Stat Pathway
Ca/cAMP/Lipid Signaling Pathway
Neuro Signaling Pathway
TGF-beta/Smad Signaling Pathway
GPCR Pathway
Ion channel Pathway
Cytochrome P450 Pathway
Others Pathway